Duration of response and progression-free survival. (A) KM estimate for DOR in patients with MCL (n = 16). (B) KM estimate for PFS in patients with MCL (N = 40). PFS (C) and DOR (D) in subgroups based on high (≥6) or low (<6) numbers of prior treatment regimens.